Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
JARID2 encodes a Jumonji- and AT-rich interaction domain (ARID)-domain-containing protein. Additionally we are shipping JARID2 Kits (3) and JARID2 Proteins (3) and many more products for this protein.
Showing 10 out of 48 products:
Human Polyclonal JARID2 Primary Antibody for WB - ABIN2787847
Olsen, Blagoev, Gnad, Macek, Kumar, Mortensen, Mann: Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. in Cell 2006
ESCs (show NR2E3 Antibodies) lacking Jarid2 show constitutive Nanog (show NANOG Antibodies) expression, reduced PCP (show BMP1 Antibodies)/Wnt (show WNT2 Antibodies) signaling and form more than one ICM upon injection to E3.5 mouse blastocysts.
Jarid2 is a novel player in iNKT cell maturation that regulates PLZF (show ZBTB16 Antibodies) expression by modulating H3K9 methylation
Jarid2 is an important component of PRC2 that has a central role in coordinating hematopoietic stem and progenitor cell function
miR (show MLXIP Antibodies)-155 regulates the fate of Th17 and Treg cells and miR (show MLXIP Antibodies)-155 contributes to Th17 cell function by suppressing the inhibitory effects of Jarid2.
Data indicate that upon stimulation of muscle cells with IFN-gamma (show IFNG Antibodies), JARID2 and other members of the Polycomb (show CBX2 Antibodies) repressive complex 2 (PRC2) were recruited to promoters to repress myogenesis.
Jarid2 exhibits nucleosome-binding activity that contributes to PRC2 stimulation
Jarid2 (Jumonji, AT rich interactive domain 2) regulates NOTCH1 (show NOTCH1 Antibodies) expression via histone modification in the developing heart.
these studies identify JARID2, MTF2 (show MTF2 Antibodies), and esPRC2p48 as important regulatory subunits of PRC2 in ES cells and reveal critical functions of these subunits
Jarid2 is required for the scheduled proliferation of epidermal stem and progenitor cells necessary to maintain epidermal homeostasis.
Endothelial Jarid2/Jumonji is required for normal cardiac development and proper Notch1 (show NOTCH1 Antibodies) expression
Data further strengthen the conclusion that JARID2 polymorphisms are associated with NSOC susceptibility.
JARID2 inhibits leukemia cell proliferation by regulating CCND1 (show CCND1 Antibodies) expression
TGF-ss-dependent expression changes of EMT (show ITK Antibodies)-related genes were inhibited by JARID2 knockdown and enhanced by JARID2 overexpression.
Results suggest a regulation loop where Jarid2 protein methylation fine-tunes polycomb (show CBX2 Antibodies) repressive complex 2 (PRC2) activity depending on the chromatin context.
Decreased miRNA-940 affects the proliferation and migration of the progenitor cells of the secondary heart field by targeting JARID2.
The interaction of JARID2 at these promoters is dependent on EED (show EED Antibodies).
Jarid2 is an important mediator of Xist-induced PRC2 targeting.
The presence of long noncoding RNAs stimulated JARID2-EZH2 (show EZH2 Antibodies) interactions in vitro and JARID2-mediated recruitment of PRC2 to chromatin.
This gene encodes a Jumonji- and AT-rich interaction domain (ARID)-domain-containing protein. The encoded protein is a DNA-binding protein that functions as a transcriptional repressor. This protein interacts with the Polycomb repressive complex 2 (PRC2) which plays an essential role in regulating gene expression during embryonic development. This protein facilitates the recruitment of the PRC2 complex to target genes. Alternate splicing results in multiple transcript variants. Mutations in this gene are associated with chronic myeloid malignancies.
jumonji, AT rich interactive domain 2
, jumonji, AT rich interactive domain 2 protein
, protein Jumonji-like
, jumonji/ARID domain-containing protein 2
, protein Jumonji
, jumonji homolog
, jumonji-like protein